Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 10 | 2021 | 986 | 2.630 |
Why?
|
| Symptom Flare Up | 2 | 2021 | 7 | 0.790 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 447 | 0.700 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 140 | 0.690 |
Why?
|
| Biomarkers | 2 | 2021 | 731 | 0.610 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2018 | 41 | 0.610 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 131 | 0.570 |
Why?
|
| Heart | 1 | 2016 | 219 | 0.490 |
Why?
|
| Heart Rate | 1 | 2016 | 374 | 0.470 |
Why?
|
| Endpoint Determination | 1 | 2013 | 17 | 0.440 |
Why?
|
| Immunotherapy | 1 | 2013 | 134 | 0.400 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2011 | 2 | 0.390 |
Why?
|
| Fasciitis | 1 | 2011 | 4 | 0.390 |
Why?
|
| Clarithromycin | 1 | 2011 | 6 | 0.390 |
Why?
|
| Panniculitis | 1 | 2011 | 4 | 0.390 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 244 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 132 | 0.330 |
Why?
|
| Humans | 12 | 2021 | 26856 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 496 | 0.280 |
Why?
|
| Cytokines | 2 | 2021 | 437 | 0.270 |
Why?
|
| Disease Progression | 2 | 2021 | 450 | 0.260 |
Why?
|
| Prognosis | 2 | 2021 | 758 | 0.250 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 74 | 0.220 |
Why?
|
| Withholding Treatment | 2 | 2019 | 20 | 0.190 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 748 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2021 | 51 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 72 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 206 | 0.180 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 56 | 0.180 |
Why?
|
| Disease Management | 1 | 2021 | 84 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 152 | 0.170 |
Why?
|
| Interferon-alpha | 1 | 2019 | 50 | 0.170 |
Why?
|
| Patient Participation | 1 | 2020 | 52 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2019 | 48 | 0.170 |
Why?
|
| Prevalence | 1 | 2021 | 469 | 0.170 |
Why?
|
| Middle Aged | 5 | 2020 | 6825 | 0.160 |
Why?
|
| Decision Making | 1 | 2020 | 169 | 0.150 |
Why?
|
| Adult | 5 | 2020 | 7389 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2021 | 2267 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2018 | 67 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 278 | 0.140 |
Why?
|
| Steroids | 1 | 2017 | 55 | 0.140 |
Why?
|
| Oklahoma | 2 | 2020 | 971 | 0.120 |
Why?
|
| Electrocardiography | 1 | 2016 | 391 | 0.120 |
Why?
|
| Male | 5 | 2020 | 12866 | 0.120 |
Why?
|
| Prednisone | 1 | 2014 | 51 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2016 | 860 | 0.110 |
Why?
|
| Female | 5 | 2020 | 14462 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 72 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2014 | 114 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 37 | 0.110 |
Why?
|
| Interferons | 1 | 2013 | 68 | 0.110 |
Why?
|
| Recurrence | 1 | 2014 | 316 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2013 | 54 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 400 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 588 | 0.100 |
Why?
|
| Health Status | 1 | 2013 | 145 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2013 | 204 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 37 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2011 | 6 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 368 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2013 | 1339 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 802 | 0.070 |
Why?
|
| Young Adult | 1 | 2011 | 2584 | 0.060 |
Why?
|
| Altruism | 1 | 2020 | 8 | 0.040 |
Why?
|
| Culture | 1 | 2020 | 26 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 21 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 62 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 89 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 82 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 399 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 172 | 0.040 |
Why?
|
| B-Cell Activating Factor | 1 | 2017 | 31 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2017 | 32 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2017 | 55 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2019 | 466 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 645 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 915 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 1219 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1564 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 5169 | 0.020 |
Why?
|